Referat / Abstract
High expression levels of the gene BAALC (brain and acute leukemia, cytoplasmic) are associated with poor prognosis in acute myeloid leukemia (AML) patients, but the underlying mechanisms are not yet understood. We evaluated the prognostic significance of expression levels of miR-3151, a newly discovered microRNA embedded in intron 1 of the BAALC gene, in a cohort of 179 older (≥60 years) cytogenetically normal AML (CN-AML) patients, in the context of established molecular markers and especially with regard to the possible interplay with its host gene BAALC. In multivariable analyses, high miR-3151 was associated with shorter disease-free and overall survival (OS), while higher BAALC expression strongly predicted failure of complete remission attainment and OS. Patients exhibiting both high miR-3151 and BAALC expression had worse outcome than patients expressing low levels of either one of the genes or both. Next, gene -and microRNA-expression profiles associated with miR-3151 expression were derived using microarrays, and a pathway analysis of the miR-3151 associated gene signature was performed using Ingenuity software. High miR-3151 expressers showed downregulation of genes involved in transcriptional regulation, post-translational modifications and cell-cycle control. Two genes of the ubiquitination pathway, FBXL20 and USP40, were experimentally validated as direct miR-3151 targets. In summary, we identified high expression levels of the intronic miR-3151 as a novel, independent prognosticator for poor outcome in CN-AML. Interestingly, miR-3151 impacted differently on outcome than its host gene BAALC; and the combination of both markers identified a patient subset with the poorest outcome, suggesting that the microRNA and its host gene contribute to clinical and prognostic features of CN-AML independently and through distinct mechanisms. This is the first example of the interplay of an intronic miR and its host gene in leukemia. Its discovery may have important biologic implications for future targeted treatment strategies.
Einführung / Introduction
Acute Myeloid Leukemia (AML) is a complex disease, which is characterized by the uncontrolled proliferation of a leukemic clone in the bone marrow. In recent years, new insights into the biology have significantly improved our understanding of AML. But, despite this progress, the outcome of the majority of AML patients still remains poor and only a fraction of the patients achieves long term survival. [1] [2] [3] The outcome is especially poor in patients aged 60 years or older, of whom only ~15% achieve a long term survival. 
Zusammenfassung / Conclusion
Since the here presented study evolved out of the aim to better understand the biology and function of BAALC, three main conclusions may be drawn.
1) We could, for the first time, demonstrate an independent prognostic impact of BAALC's intronic microRNA miR-3151. In addition, we could validate the important prognostic impact of BAALC expression in older CN-AML patients, especially on the achievement of CR and OS.
2) Both genes impacted on different outcome endpoints and showed also differences in their associated gene-expression signatures. Thus, neither does miR-3151 explain -in full -the impact of BAALC expression levels (BAALC is not only a meaningless cover gene), nor does BAALC account for the impact of miR-3151 expression levels.
3) BAALC and miR-3151 may have to be interpreted as an oncogenic locus, which interplays towards leukemogenesis.
Within the scope of this thesis we present a study that reported miR-3151 as an independent prognostic factor for outcome in older patients with CN-AML. The impact of miR-3151 expression on survival probability was independent from other, wellestablished molecular markers (eg, NPM1 mutations and FLT3-ITD) and notably also independent from the expression status of its host gene BAALC. Importantly, higher expression of miR-3151 impacted on different outcome endpoints than BAALC: The effect of BAALC was mainly on achievement of CR while that of miR-3151 was mainly on outcome-once CR had been achieved (DFS); naturally then both BAALC and miR-3151 affected OS in these older patients. Patients with high expression levels of both genes were identified as the patient subset with the poorest outcome. In general, patients who had high expression of both miR-3151 and BAALC did worst, patients with low expression of both genes did best, and patients with discordant expresser status had intermediate outcomes. Therefore, we performed a global gene-expression profiling in our patient cohort and were able to derive a distinct gene-expression signature associated with high miR-3151 expression levels. Using ingenuity software, we next performed a detailed gene ontology analysis to identify genes and subsequent pathways which are enriched in high miR-3151 expressing patients. This gene ontology analysis revealed pathways regulating gene expression, cell-cycle control and post-transcriptional regulation to be primarily affected by high miR-3151 expression levels. As a next step, we aimed to validate two of the most downregulated genes of the miR-3151-associated signature as direct miR-3151 targets. For identification of these genes, we used a significance-based algorithm. Interestingly, 2 out of the 6 genes which fulfilled our selection criteria belonged to the ubiquitination pathway 44 -which goes in line with our previous observation that miR-3151 impacts on post-transcriptional regulation pathways. Both genes, FBXL20 45 and USP40 46 could be validated as direct miR-3151 target genes.
FBXL20 belongs to the F-BOX proteins and is -as a part of the SCF (Skp, Cullin, F-box containing) -complex -responsible for the ubiquitination and consecutive degradation of its target genes. 45 The SCF-complex is a multiprotein complex catalyzing the ubiquitination of proteins destined for degradation, in which the F-box proteins (eg, FBXL20) contribute to the specificity of the complex, since they are the part which is binding to the target proteins. This protein-"capture" then allows the ubiquitin ligase (eg, E2) to attach the ubiquitin label (Figure 1 ).
So far, nothing is known about specific FBXL20 targets. However, the identification of such genes may be an interesting topic of future research to further understand the downstream biology of high miR-3151 expression levels and to potentially find new links in the complex networking of AML signaling pathways. Since we already have a successfully working antibody for FBXL20, which has been used for Western blotting in the publication, a next step may be the immunoprecipitation and consecutive massspectrometric analysis to identify the proteins bound to FBXL20.
The comparison of the miR-3151-associated gene-and microRNA-expression signatures with the gene-and microRNA-expression signatures previously reported to be associated with high expression levels of the host gene BAALC led to additional important observations. Despite the strong association of the expression levels of both genes, interesting differences in the differentially expressed genes in both signatures could be observed. While high BAALC expression was associated with high expression of the stemness-markers PROM1 and CD34, no such association could be observed in high miR-3151 expressing patients. In contrast, downregulation of the let-7 family, which was the key-feature of the miR-3151-associated microRNA-expression signature, has not been observed in high BAALC expressing patients.
Interestingly, in one of the initial studies of BAALC, Baldus et al. suggested that high BAALC expression may lose its prognostic importance in patients undergoing allogeneic hematopoietic stem cell transplantation (HCT). 22 Thus, as a pilot study, we measured pre-treatment BAALC and miR-3151 expression levels in a total of 75 older AML patients with mixed karyotypes, which underwent allogeneic HCT at the University of
Leipzig. In these patients we also assessed the NPM1 mutation status. Similarly to the observations in the patients from the Cancer and Leukemia Group B (CALGB) study (presented study) we observed an association of high BAALC and high miR-3151
expresser status -using a median cut for both genes to define high and low expressers -with NPM1 wild-type (P=0.0024 and P=0.013, respectively). Furthermore, again validating our findings of the CALGB patient set, we observed an association between high BAALC and high miR-3151 expresser status in the Leipzig patient set (P=.04).
However, about 40% (n=30) of the patients had a discordant expresser status of the two genes. For a subset of the investigated Leipzig patients (n=22) follow-up data for a preliminary outcome analysis was available. Utilizing the Kaplan-Meier Method, we analyzed the OS according to the BAALC and miR-3151 expresser status. In this analysis, both miR-3151 and BAALC failed as a single marker to significantly separate the patients according to their overall survival (Figure 2A and B).
However, when following the proposal to analyze the combined effect of the BAALC/miR-3151 locus, we observed a significantly shorter OS (P=.05; log-rank test) in patients with high expression of BAALC, miR-3151 or both when compared to patients expressing both genes on low levels ( Figure 3 ).
Even though the analyzed groups are very small, these data may give further support to the importance of the combined effect of the BAALC/miR-3151 locus. In conclusion, the here presented manuscript is not only the first report of the prognostic importance of a novel microRNA miR-3151, but it is the first example of an interaction between an intronic miR and its host gene in AML. Since so far the impact of intronic miRs on the effects of their host genes has been vastly overlooked, this discovery may initiate new research in the pathways of other human malignancies in which genes with intronic miRs are involved. In the case of BAALC and miR-3151, we may conclude that high expression of both oncogenes is important to promote leukemogenesis, since both are impacting on different downstream pathways and ultimately different outcome endpoints.
Nothing is known about the downstream targets about BAALC yet, but since we could validate two members of the ubiquitination pathway as direct miR-3151 target genes, it may be tempting to speculate that BAALC may either also be involved in the ubiquitination pathway or that the repressed ubiquitination (and consecutive degradation) of the FBXL20 targets may directly or indirectly support the function of
BAALC.
The further characterization of the interplay of miR-3151 and its host gene BAALC may unravel novel pathways, which may lead to a better understanding of the pathogenesis of AML. 
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